Annette Sievers

Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule

John J Scarcelli, Jeffrey K. Marshall, Eric A Sousa, 2021, Biotechnology progress.

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Jeffrey R. Chabot, Denise M O'Hara, W. Somers, 2018, Scientific Reports.

Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease

James R. Apgar, R. Kriz, X. Zhong, 2020, The Journal of Biological Chemistry.

Transient CHO expression platform for robust antibody production and its enhanced N‐glycan sialylation on therapeutic glycoproteins

W. Somers, R. Kriz, X. Zhong, 2018, Biotechnology progress.

Development of a long acting human growth hormone analog suitable for once a week dosing.

Danielle E. Dettling, Mark Horn, F. Brunel, 2013, Bioorganic & medicinal chemistry letters.

Equilibrium of formation of the 6-carbanion of UMP, a potential intermediate in the action of OMP decarboxylase.

R. Wolfenden, Annette Sievers, 2002, Journal of the American Chemical Society.

Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance.

Annette Sievers, Désirée H H Tsao, L. Mosyak, 2010, Journal of medicinal chemistry.

The ribosome as an entropy trap.

Annette Sievers, Malte Beringer, Richard Wolfenden, 2004, Proceedings of the National Academy of Sciences of the United States of America.

The effective molarity of the substrate phosphoryl group in the transition state for yeast OMP decarboxylase.

R. Wolfenden, Annette Sievers, 2005, Bioorganic chemistry.

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation

Jeffrey R. Chabot, Liliana Wroblewska, Yan Liu, 2021, Scientific Reports.

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Jeffrey R. Chabot, Denise M O'Hara, W. Somers, 2018, Scientific Reports.